BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 22127594)

  • 1. General insufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients' medical treatment or underlying diseases.
    Schlaf G; Mauz-Körholz C; Ott U; Leike S; Altermann W
    Histol Histopathol; 2012 Jan; 27(1):31-8. PubMed ID: 22127594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid phase-based cross-matching as solution for kidney allograft recipients pretreated with therapeutic antibodies.
    Schlaf G; Apel S; Wahle A; Altermann WW
    Biomed Res Int; 2015; 2015():587158. PubMed ID: 25654115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic flow cytometric crossmatch in renal transplantation: a single assay to simultaneously detect antibody binding and cytotoxicity.
    Thammanichanond D; Athimang W; Paisooksantivatana K; Mongkolsuk T; Ingsathit A; Worawichawong S; Kitpoka P; Jirasiritham S; Kantachuvesiri S
    Transplant Proc; 2012 Jan; 44(1):62-5. PubMed ID: 22310580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study between cytotoxicity and flowcytometry crossmatches before and after renal transplantation.
    Abdel Rahman AS; Fahim NM; El Sayed AA; El Hady SA; Ahmad YS
    Egypt J Immunol; 2005; 12(2):77-89. PubMed ID: 17977213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luminex Solid-Phase Crossmatch for De Novo Donor-Specific Antibodies in Living-Donor Related Transplants.
    Mehrotra S; Sharma RK; Mayya M; Gupta A; Prasad N; Kaul A; Bhadauria DS
    Exp Clin Transplant; 2017 Aug; 15(4):394-399. PubMed ID: 28447925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation.
    Gloor JM; DeGoey S; Ploeger N; Gebel H; Bray R; Moore SB; Dean PG; Stegall MD
    Transplantation; 2004 Jul; 78(2):221-7. PubMed ID: 15280682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation.
    Morris GP; Phelan DL; Jendrisak MD; Mohanakumar T
    Hum Immunol; 2010 Mar; 71(3):268-73. PubMed ID: 20074605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel ELISA-based crossmatch procedure to detect donor-specific anti-HLA antibodies responsible for corneal allograft rejections.
    Sel S; Schlaf G; Schurat O; Altermann WW
    J Immunol Methods; 2012 Jul; 381(1-2):23-31. PubMed ID: 22561526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
    Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
    Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure.
    Altermann WW; Seliger B; Sel S; Wendt D; Schlaf G
    Histol Histopathol; 2006 Oct; 21(10):1115-24. PubMed ID: 16835834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation.
    Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Hallar M; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Transpl Immunol; 2008 Nov; 20(1-2):61-7. PubMed ID: 18929659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified flow cytometry crossmatch detecting alloantibody-related cytotoxicity as a way to distinguish lytic antibodies from harmless in allosensitised kidney recipients.
    Zieliński M; Zielińska H; Moszkowska G; Dȩbska-Ślizień A; Rutkowski B; Trzonkowski P
    Transplant Proc; 2013; 45(1):88-94. PubMed ID: 23375279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assignment of C1q-binding HLA antibodies as unacceptable HLA antigens avoids positive CDC-crossmatches prior to transplantation of deceased donor organs.
    Juhl D; Marget M; Hallensleben M; Görg S; Ziemann M
    Transpl Immunol; 2017 Mar; 41():17-21. PubMed ID: 28088367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance.
    Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N
    Clin Transpl; 2011; ():223-35. PubMed ID: 22755416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.
    Ata P; Canbakan M; Kara M; Özel L; Ünal E; Titiz Mİ
    Transplant Proc; 2012; 44(6):1652-5. PubMed ID: 22841237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of donor-specific antibody detection in first-graft renal transplant recipients with a negative complement-dependent cytotoxic crossmatch.
    Mahmoud KM; Ismail AM; Sheashaa HA; Gheith OA; Kamal MM; Ghoneim MA
    Exp Clin Transplant; 2009 Jun; 7(2):124-8. PubMed ID: 19715518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved flow cytometry based cytotoxicity and binding assay for clinical antibody HLA crossmatching.
    Alheim M; Paul PK; Hauzenberger DM; Wikström AC
    Hum Immunol; 2015 Nov; 76(11):849-57. PubMed ID: 26429307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.